The principal finding of this study is that among patients with type II diabetes and mixed dyslipidemia, treatment with simvastatin, fenofibrate, or their combination was associated with reductions in inflammatory biomarkers high-sensitivity C-reactive protein (hsCRP) and lipoprotein-associated phospholipase A2 (Lp-PLA2).